Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma

NCT01833299 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT01833299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01833299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2010
Completion date
December 31, 2018
Enrollment
120 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

face cancer, hepatocellular carcinoma